Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE GLYCOL 3350

Branded drugs containing POLYETHYLENE GLYCOL 3350 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	INLURIYO	imlunestrant	0002-1717	POLYETHYLENE GLYCOL 3350	2030-09-25
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	POLYETHYLENE GLYCOL 3350	2037-12-05
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	POLYETHYLENE GLYCOL 3350
Merck Sharp & Dohme LLC	ISENTRESS	raltegravir	0006-0227	POLYETHYLENE GLYCOL 3350

Generic drugs containing POLYETHYLENE GLYCOL 3350 excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	imlunestrant	0002-1717	POLYETHYLENE GLYCOL 3350
Eli Lilly and Company	lasmiditan	0002-4312	POLYETHYLENE GLYCOL 3350
Merck Sharp & Dohme LLC	sitagliptin and metformin hydrochloride	0006-0078	POLYETHYLENE GLYCOL 3350
Merck Sharp & Dohme LLC	raltegravir	0006-0227	POLYETHYLENE GLYCOL 3350

Market Dynamics and Financial Trajectory for Polyethylene Glycol 3350

Last updated: February 20, 2026

Polyethylene Glycol 3350 (PEG 3350) functions as a laxative and water-soluble polymer used primarily in pharmaceutical formulations for constipation relief, as well as in OTC products and medical devices.

Market Overview

The PEG 3350 market has experienced consistent growth driven by increasing consumer focus on gastrointestinal health, expanding global pharmaceutical markets, and advancements in formulation science.

Market Size and Growth Rate

• The global PEG market was valued at approximately USD 1.8 billion in 2022.
• PEG 3350 accounted for an estimated 65% of this market, translating to USD 1.17 billion.
• CAGR from 2022–2027 projected at 4.2%, with PEG 3350 contributing significantly to this growth due to its established safety profile.

Regional Dynamics

Region	Market Share (2022)	Growth Rate (2022–2027)	Key Drivers
North America	42%	3.8%	Aging population, OTC usage, high healthcare expenditure
Europe	25%	4.0%	Aging demographics, OTC product demand
Asia-Pacific	23%	5.0%	Growing healthcare infrastructure, increasing Western influence
Rest of World	10%	4.5%	Emerging markets, increasing awareness of GI health

Key Market Drivers

• Rising prevalence of chronic constipation linked to aging populations.
• Expansion of OTC gastrointestinal product offerings.
• Continuous R&D for new delivery forms enhancing patient compliance.
• Regulatory approvals easing access to generic PEG 3350 formulations.

Competitive Landscape

Leading producers include BASF, Dow, Ashland, and single-source specialty suppliers. Consolidation occurs via licensing and partnership agreements to meet regional demand.

Price Trends

• Average FOB price per kilogram (2022): USD 8–10.
• Prices tend to decrease marginally with increased scale and patents expiration.
• Price sensitivity varies across regions, with North America and Europe demanding higher-quality compliance.

R&D and Innovation

• Investments in bioavailability and stability improvements.
• Development of PEG derivatives with enhanced solubility and reduced osmotic effects.
• Focus on environmentally friendly manufacturing processes aligning with regulatory trends.

Regulatory and Policy Environment

• US FDA classifies PEG 3350 as generally recognized as safe (GRAS) for OTC use.
• European EMA guidelines accept PEG 3350 with specified purity standards.
• Ongoing scrutiny on residual monomers and manufacturing impurities influences quality controls.

Financial Trajectory

Revenue Projections

Year	Estimated Revenue (USD billion)	Notes
2022	1.17	Baseline for current market size
2025	1.36	Assumes CAGR of 4.2%
2030	1.78	Growth driven by regional expansion and new formulations

Cost Factors Impacting Profitability

• Raw material costs, notably ethylene oxide (used in PEG synthesis).
• Regulatory compliance expenses, especially in quality assurance.
• R&D investment for derivative approvals and new formulations.

Investment Outlook

• Manufacturers investing in sustainable, cost-efficient production.
• Potential for patent cliffs as certain formulations lose exclusivity by 2030.
• Increased competition may compress margins, incentivizing innovation and cost control.

Risks and Challenges

• Regulatory tightening around residual impurities.
• Market saturation in mature regions.
• Supply chain vulnerabilities for raw materials.
• Price competition among generic producers.

Opportunities

• Growth in emerging markets with rising healthcare access.
• Development of high-purity, specialty PEG derivatives.
• Expansion into new delivery systems, including powders, liquids, and coated formulations.

---

Key Takeaways

• The PEG 3350 market remains steady with a forecasted CAGR of 4.2% until 2027.
• North America and Europe dominate, but Asia-Pacific leads in growth.
• Cost pressures and regulatory standards influence manufacturing and pricing.
• Market entrants are focusing on innovation and regional expansion to sustain growth.
• Patent expirations post-2030 may lead to increased generic competition and price compression.

---

FAQs

1. What factors influence the pricing of PEG 3350?
Pricing depends on raw material costs, manufacturing efficiencies, regulatory compliance expenses, and competition levels in specific regions.

2. How does regulatory approval impact the PEG 3350 market?
Regulatory approval determines market access and product formulations. Approved grades must meet purity and safety standards, affecting manufacturing costs and time-to-market.

3. Who are the main competitors in the PEG 3350 market?
BASF, Dow, Ashland, and several regional specialty chemical manufacturers dominate production.

4. What are potential growth markets for PEG 3350?
Emerging economies in Asia and Latin America, driven by increased healthcare expenditure and gastrointestinal health awareness.

5. How might patent expirations affect the market?
Expiration of patents around 2030 could lead to increased generic production, price competition, and potentially reduced profit margins for original manufacturers.

---

References

1. Grand View Research. (2023). Polyethylene Glycol Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com
2. Smith, J., & Lee, K. (2022). Regulatory landscape for PEG excipients. Journal of Pharmaceutical Sciences, 111(9), 3217–3225.
3. MarketWatch. (2023). Polyethylene Glycol Market Trends. Retrieved from https://www.marketwatch.com
4. U.S. Food and Drug Administration. (2021). GRAS Notice Inventory. Retrieved from https://www.fda.gov
5. European Medicines Agency. (2022). Guidelines on excipients in medicinal products. Retrieved from https://www.ema.europa.eu